US 11,891,445 B1
Anti-B7-H3 antibody and use thereof
Kyeongsu Park, Seongnam-si (KR); Yangsoon Lee, Seongnam-si (KR); Hyejin Chung, Seongnam-si (KR); Uijung Jung, Seongnam-si (KR); Yong-Gyu Son, Seongnam-si (KR); Sang-Jun Ha, Seongnam-si (KR); Myeong Joon Kim, Seongnam-si (KR); Eunyoung Park, Seongnam-si (KR); Kyungjin Park, Seongnam-si (KR); Eunsil Sung, Seongnam-si (KR); Yeunju Kim, Seongnam-si (KR); Jinhyung Ahn, Seongnam-si (KR); Byungje Sung, Seongnam-si (KR); Daehae Song, Seongnam-si (KR); and Youngdon Pak, Seongnam-si (KR)
Assigned to ABL BIO INC., Seongnam-si (KR)
Appl. No. 17/057,643
Filed by ABL Bio Inc., Seongnam-si (KR)
PCT Filed May 24, 2019, PCT No. PCT/KR2019/006270
§ 371(c)(1), (2) Date Nov. 20, 2020,
PCT Pub. No. WO2019/226017, PCT Pub. Date Nov. 28, 2019.
Claims priority of application No. 10-2018-0059257 (KR), filed on May 24, 2018; and application No. PCT/KR2018/005968 (WO), filed on May 25, 2018.
Int. Cl. C07K 16/28 (2006.01); G01N 33/574 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2827 (2013.01) [A61P 35/00 (2018.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/70532 (2013.01)] 14 Claims
 
1. An isolated antibody specifically recognizing B7-H3 or its antigen-binding fragment,
wherein the antibody or antigen-binding fragment comprises (i) heavy chain complementarity determining regions of CDRH1, CDRH2 and CDRH3, and (ii) light chain complementarity determining regions of CDRL1, CDRL2 and CDRL3, and wherein,
(a) the CDRH1, CDRH2 and CDRH3 are SEQ ID NOs: 1, 5, and 10, respectively, and the CDRL1, CDRL2, and CDRL3 are SEQ ID NOs: 15, 20 and 25, respectively;
(b) the CDRH1, CDRH2 and CDRH3 are SEQ ID NOs: 2, 6, and 11, respectively, and the CDRL1, CDRL2, and CDRL3 are SEQ ID NOs: 16, 21 and 26, respectively;
(c) the CDRH1, CDRH2 and CDRH3 are SEQ ID NOs: 3, 7, and 12, respectively, and the CDRL1, CDRL2, and CDRL3 are SEQ ID NOs: 17, 22 and 27, respectively;
(d) the CDRH1, CDRH2 and CDRH3 are SEQ ID NOs: 1, 8, and 13, respectively, and the CDRL1, CDRL2, and CDRL3 are SEQ ID NOs: 18, 23 and 28, respectively;
(e) the CDRH1, CDRH2 and CDRH3 are SEQ ID NOs: 4, 9, and 14, respectively, and the CDRL1, CDRL2, and CDRL3 are SEQ ID NOs: 19, 24 and 29, respectively
(f) the CDRH1, CDRH2 and CDRH3 are SEQ ID NOs: 3, 68, and 12, respectively, and the CDRL1, CDRL2, and CDRL3 are SEQ ID NOs: 17, 22, and 27, respectively; or
(g) the CDRH1, CDRH2 and CDRH3 are SEQ ID NOs: 3, 68, and 12, respectively, and the CDRL1, CDRL2, and CDRL3 are SEQ ID NOs: 17, 69, and 27, respectively.